» Articles » PMID: 34696874

Regulation of Glutamate Signaling in the Extended Amygdala by Adolescent Alcohol Exposure

Overview
Date 2021 Oct 26
PMID 34696874
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Adolescence is a critical period for brain development and behavioral maturation, marked by increased risk-taking behavior and the initiation of drug use. There are significant changes in gray matter volume and pruning of synapses along with a shift in excitatory to inhibitory balance which marks the maturation of cognition and decision-making. Because of ongoing brain development, adolescents are particularly sensitive to the detrimental effects of drugs, including alcohol, which can cause long-lasting consequences into adulthood. The extended amygdala is a region critically implicated in withdrawal and negative affect such as anxiety and depression. As negative affective disorders develop during adolescence, the effects of adolescent alcohol exposure on extended amygdala circuitry needs further inquiry. Here we aim to provide a framework to discuss the existing literature on the extended amygdala, the neuroadaptations which result from alcohol use, and the intersection of factors which contribute to the long-lasting effects of this exposure.

Citing Articles

Potential Link Between Exercise and N-Methyl-D-Aspartate Glutamate Receptors in Alcohol Use Disorder: Implications for Therapeutic Strategies.

Sedhom S, Hammond N, Thanos K, Blum K, Elman I, Bowirrat A Psychol Res Behav Manag. 2024; 17:2363-2376.

PMID: 38895648 PMC: 11185169. DOI: 10.2147/PRBM.S462403.


Epigenetic regulation of microglia and neurons by proinflammatory signaling following adolescent intermittent ethanol (AIE) exposure and in human AUD.

Crews F, Macht V, Vetreno R Adv Drug Alcohol Res. 2024; 4:12094.

PMID: 38524847 PMC: 10957664. DOI: 10.3389/adar.2024.12094.


Regulation of alcohol drinking by ventral striatum and extended amygdala circuitry.

Borrego M, Chan A, Ozburn A Neuropharmacology. 2022; 212:109074.

PMID: 35487273 PMC: 9677601. DOI: 10.1016/j.neuropharm.2022.109074.